TRIGO-GROUP
15.5.2019 10:02:07 CEST | Business Wire | Press release
TRIGO Group, a global leader of quality solutions for the transportation industry has acquired EMC Consulting, a top Romanian quality training company. By combining expertise, the merge aims to spear-head quality improvements for customers’ production processes.
TRIGO has served more than 8,000 customers over the past 22 years worldwide. Over the past 12 years, EMC Consulting has served over 50 multinational companies in Romania. Our partnership enables EMC Consulting to extend its market reach beyond Romania to more than 25 countries serviced by TRIGO. In addition, TRIGO’s experience is further enhanced by EMC Consulting’s extensive training portfolio and local expertise.
EMC Consulting is highly regarded within the manufacturing market. They have trained more than 5,000 people in 35 training courses, covering both theoretical and practical quality knowledge including manufacturing, logistics, continuous improvement, and project management. Their client portfolio includes key players in the automotive industry, such as IRUM, Continental, and Adient.
Ovidiu Veghes, Country Manager for TRIGO Romania, worked closely in finalizing the acquisition. He stated, “EMC Consulting fits perfectly with our service portfolio. Our customer collaborations will be further strengthened.”
Constantin Pătășanu, CEO of EMC Consulting, said, “I am convinced that our common goals will speed up our development. I am excited to utilize our quality knowledge with TRIGO and offer more diverse services made up of training and consultancy aspects.”
Zsolt Puskás, EVP of the TREQ division which oversees training and consultancy operations for TRIGO, commented, “EMC Consulting distinguishes itself by going beyond standard quality requirements, providing solutions that embrace adaptability and creativity. They are a proven group of experts improving the effectiveness of production.”
About EMC Consulting
Founded in 2007, EMC Consulting is a training and consulting company with certified trainers and consultants according to IATF, ISO, VDA, REFA, and PMI. Their portfolio includes topics like lean manufacturing, lean six sigma, process engineering and logistics management. They support organizations in finding simple, creative, and customized quality solutions. Visit: https://emctm.ro
About TRIGO Group
Founded in 1997, TRIGO Group is a Global Quality Solutions provider for the transportation sector, focused on automotive and aerospace industries. With more than 10,000 professionals present in 25 countries, TRIGO offers a comprehensive portfolio of services including quality engineering, rework, inspection, auditing, training, consulting, and project management. Visit: https://trigo-group.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190515005054/en/
Contact:
Elaine Regas EVP, Global Sales & Marketing elaine.regas@trigo-group.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom